CLYM Overview

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is10.50 USD with a low forecast of 10.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Climb Bio Inc revenue for the last quarter amounts to -19.30M USD, increased 155.47

Climb Bio Inc. EPS for the last quarter amounts to -15635000.00 USD, increased 183.19

Climb Bio Inc (CLYM) has 28 emplpoyees as of April 28 2026.

Today CLYM has the market capitalization of 436.60M USD.